N-terminally His-tagged hepatitis B core antigens: Construction, expression, purification and antigenicity

被引：20
作者：
Yap, Wei Boon [1 ]
Tey, Beng Ti [2 ,3 ]
Ng, Michelle Y. T. [2 ]
Ong, Swee Tin [1 ]
Tan, Wen Siang [1 ,2 ]
机构：
[1] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Microbiol, Serdang 43400, Selangor, Malaysia
[2] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor, Malaysia
[3] Univ Putra Malaysia, Fac Engn, Dept Chem & Environm Engn, Serdang 43400, Selangor, Malaysia
来源：
JOURNAL OF VIROLOGICAL METHODS | 2009年 / 160卷 / 1-2期
关键词：
Hepatitis B capsid; Protein display; His-tag; Purification; Antigenicity; METAL AFFINITY-CHROMATOGRAPHY; NUCLEOCAPSID PROTEIN; ESCHERICHIA-COLI; ELECTRON CRYOMICROSCOPY; FOREIGN EPITOPES; CAPSID PROTEIN; VIRUS; PARTICLES; MICE; CRYSTALLIZATION;
D O I：
10.1016/j.jviromet.2009.04.038
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
The core antigen of the hepatitis B virus (HBcAg) has been used widely as a diagnostic reagent for the identification of the viral infection. However, purification using the conventional sucrose density gradient ultracentrifugation is time consuming and costly. To overcome this, HBcAg particles displaying His-tag on their surface were constructed and produced in Escherichia coli. The recombinant His-tagged HBcAgs were purified using immobilized metal affinity chromatography. Transmission electron microscopy and enzyme-linked immunosorbent assay (ELISA) revealed that the displayed His-tag did not impair the formation of the core particles and the antigenicity of HBcAg. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码：125 / 131
页数：7
相关论文
共 32 条
[1]   Determination of the fold of the core protein of hepatitis B virus ky electron cryomicroscopy [J].
Bottcher, B ;
Wynne, SA ;
Crowther, RA .
NATURE, 1997, 386 (6620) :88-91
[2]   Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1 [J].
Bourne, Christina R. ;
Finn, M. G. ;
Zlotnick, Adam .
JOURNAL OF VIROLOGY, 2006, 80 (22) :11055-11061
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Expression, purification and characterization of full-length RNA-free hepatitis B core particles [J].
Broos, Katleen ;
Vanlandschoot, Peter ;
Maras, Marleen ;
Robbens, Johan ;
Leroux-Roels, Geert ;
Guisez, Yves .
PROTEIN EXPRESSION AND PURIFICATION, 2007, 54 (01) :30-37
[5]   FOREIGN EPITOPES IN IMMUNODOMINANT REGIONS OF HEPATITIS-B CORE PARTICLES ARE HIGHLY IMMUNOGENIC AND CONFORMATIONALLY RESTRICTED [J].
BROWN, AL ;
FRANCIS, MJ ;
HASTINGS, GZ ;
PARRY, NR ;
BARNETT, PV ;
ROWLANDS, DJ ;
CLARKE, BE .
VACCINE, 1991, 9 (08) :595-601
[6]   Hepatitis B virus capsid: Localization of the putative immunodominant loop (Residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens [J].
Conway, JF ;
Cheng, N ;
Zlotnick, A ;
Stahl, SJ ;
Wingfield, PT ;
Belnap, DM ;
Kanngiesser, U ;
Noah, M ;
Steven, AC .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 279 (05) :1111-1121
[7]   Localization of the N terminus of hepatitis B virus capsid protein by peptide-based difference mapping from cryoelectron microscopy [J].
Conway, JF ;
Cheng, N ;
Zlotnick, A ;
Stahl, SJ ;
Wingfield, PT ;
Steven, AC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14622-14627
[8]   3-DIMENSIONAL STRUCTURE OF HEPATITIS-B VIRUS CORE PARTICLES DETERMINED BY ELECTRON CRYOMICROSCOPY [J].
CROWTHER, RA ;
KISELEV, NA ;
BOTTCHER, B ;
BERRIMAN, JA ;
BORISOVA, GP ;
OSE, V ;
PUMPENS, P .
CELL, 1994, 77 (06) :943-950
[9]   Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques [J].
Fuller, Deborah Heydenburg ;
Shipley, Tim ;
Allen, Todd M. ;
Fuller, James T. ;
Wu, Mary S. ;
Horton, Helen ;
Wilson, Nancy ;
Widera, Georg ;
Watkins, David I. .
VIROLOGY, 2007, 364 (02) :245-255
[10]   A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies [J].
Geldmacher, A ;
Skrastina, D ;
Borisova, G ;
Petrovskis, I ;
Krüger, DH ;
Pumpens, P ;
Ulrich, R .
VACCINE, 2005, 23 (30) :3973-3983
1234